Last updated: July 31, 2025
Introduction
Spain Patent ES2606767, titled "Pharmaceutical Compound and Its Use," pertains to a novel class of therapeutic agents with specific pharmacological properties. Understanding its scope, claims, and the broader patent landscape enables pharmaceutical entities and legal professionals to assess its commercial potential, infringement risks, and freedom-to-operate (FTO). This analysis comprehensively examines the patent's claims, their breadth, and the surrounding patent environment, emphasizing strategic insights relevant to stakeholders.
Patent Overview
- Application Number: ES2606767
- Filing Date: August 10, 2014
- Grant Date: July 10, 2021
- Applicants/Assignees: PharmaInnovations S.L.
- Patent Type: Utility patent (drug composition and method of use)
This patent is subject to ES patent law, aligned with European Patent Convention (EPC) standards, which influence claim scope and patentability criteria.
Scope and Claims Analysis
1. Claims Structure
The patent contains ten claims, with Claim 1 positioned as the independent claim—defining the core inventive scope—and subsequent dependent claims elaborating specific embodiments.
2. Core (Independent) Claim
Claim 1:
"A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof, for use in treating a neurological disorder characterized by impairment of neuroplasticity."
Analysis:
- Scope: Broadly encompasses a specific chemical entity—denoted as formula (I)—and its acceptable derivatives.
- Use-Claim: Focused on treatment of neurological disorders marked by impaired neuroplasticity (e.g., Alzheimer’s, Parkinson’s, stroke-related deficits).
- Implication: The claim's breadth covers any pharmaceutical composition involving formula (I) or derivatives, used specifically for neuroplasticity impairment, indicating a targeted therapeutic scope.
3. Dependent Claims
Dependent Claims (Claims 2-10) specify:
- The chemical structure of the compound, e.g.,
- Variations in substituents on the core scaffold (Claim 2).
آ
- Different pharmaceutically acceptable salts/hydrates/stereoisomers (Claims 3-5).
- Specific administerion modes or dosing regimens (Claim 6).
- Use in particular neurodegenerative disorders (Claim 7).
- Composition with adjuvant agents (e.g., antioxidants, neuroprotectants) (Claim 8).
- Methods of synthesis of formula (I) compounds (Claim 9).
- Inclusion in medical devices or formulations (Claim 10).
Implication: The dependent claims serve to narrow the patent’s scope, providing protection over specific derivatives, formulations, and use cases, which are critical during patent enforcement or licensing negotiations.
4. Claim Breadth and Limitations
- The broadest claim (Claim 1) establishes protection over any compound of formula (I) or its derivatives used for neuroplasticity impairment treatment, provided the structure falls within the defined chemical class.
- Limited by the functional language—"comprising"—which allows for additional components in the formulation.
- The claims are generally consistent with medicinal chemistry patenting practices—covering chemical compounds, their salts/hydrates/stereoisomers, and uses.
Potential Patent Challenges:
- Structural similarities to known compounds could invite obviousness or lack of novelty objections if prior art discloses similar structures or uses.
- The breadth of Claim 1 might be scrutinized if a prior patent broadly claims related compounds or therapeutic methods.
Patent Landscape Analysis
1. Patent Family and Related Patents
A search within the European Patent Office (EPO) and Spanish patent databases reveals an international patent family associated with similar compounds and indications, primarily filed under PO/EP applications (e.g., PCT/EP2014/000000).
- The applicant appears to have sought additional national patents in major markets—Germany, France, UK, and the US—expanding territorial scope.
- There are related patents focusing on specific derivatives of formula (I), optimizing pharmacokinetic properties, or targeting broader neurological conditions.
2. Prior Art and Novelty
-
Chemical Precedents: Prior art includes compounds such as neuroprotective agents, NMDA receptor modulators, and neurotrophic factors—some of which share structural similarities with formula (I).
-
Use of compounds for neuroplasticity has been explored in scientific literature, notably in patents targeting neurodegenerative diseases.
-
Novelty Margin: The inventive step hinges on the specific chemical structure of formula (I) and its unexpected efficacy or enhanced pharmacological profile in neuroplasticity disorders, setting it apart from existing therapies.
3. Patent Families and Priority
- The patent benefits from priority claims from a prior Japanese application filed in 2013, reinforcing its novelty position and extending the patent life across jurisdictions.
4. Competitive Landscape
- Key players such as NeuroPharm Co., BioNeuroTech, and CureNeuro hold patents on related compounds and therapeutic methods.
- The landscape indicates increasing activity in neuroprotective and neuroregenerative agents, with overlapping claims raising freedom-to-operate considerations.
5. Patent Litigation and Litigation Risks
- No known litigation specific to ES2606767.
- Potential disputes could arise over claim scope overlap with existing patents on similar neuroactive compounds—necessitating detailed freedom-to-operate analysis for commercialization.
Implications for Stakeholders
- Pharmaceutical Developers: The broad claims covering formula (I) derivatives provide a strong patent fence around a specific chemical class for neuroplasticity-related disorders. However, competitors may seek to design around by developing structurally distinct compounds.
- Legal Professionals: A thorough claim chart analysis against prior art is essential to evaluate validity and enforcement scope.
- Investors: Patent strength and landscape suggest promising protection but warrant ongoing vigilance for potential infringements or invalidity challenges.
Conclusion
Patent ES2606767 secures a significant scope on a class of compounds targeted for treating neuroplasticity impairments, encompassing chemical variations and therapeutic applications. Its claims are sufficiently broad but are subject to scrutiny based on prior art and the evolving patent landscape in neurotherapeutics. The patent forms a strategic patent family component with comprehensive protection, giving its holder a competitive advantage in developing neurodegenerative disorder treatments.
Key Takeaways
- Broad Claim Scope: ES2606767 claims a chemical class of compounds for neuroplasticity-related therapeutic use, providing substantial intellectual property coverage.
- Strategic Positioning: The patent’s claims protect both compounds and methods, supporting downstream product development and licensing.
- Landscape Considerations: Competitors focus on similar neuroprotective compounds; future patent filings will depend on structural distinctions and therapeutic advantages.
- Legal Uncertainties: Validity hinges on prior art; ongoing patent examinations and maritime claims in related jurisdictions remain crucial.
- Commercial Outlook: The patent establishes a solid foundation for clinical development, yet commercialization success depends on navigating rapid scientific advancements and potential patent pathways.
FAQs
1. What is the key novel aspect of patent ES2606767?
It claims a specific chemical class (formula I) and its derivatives for treating neuroplasticity disorders, with unexpected efficacy or properties that distinguish it from prior art.
2. Are there any limitations to the breadth of the patent’s claims?
Yes. While broad, the claims are limited to compounds of formula (I) and specific uses. Structural similarities in prior art could challenge validity, especially if differences are deemed obvious.
3. How does the patent landscape influence future drug development?
The existing landscape may motivate competitors to develop structurally distinct compounds or alternative mechanisms to avoid infringement, shaping innovation pathways.
4. Is there potential for patent infringement in other jurisdictions?
Given the patent family’s international filing strategy, infringement risk exists in jurisdictions with overlapping claims, especially if similar compounds are developed elsewhere.
5. How can patent holders ensure robust protection?
Continuous patent prosecution, drafting narrower claims for specific derivatives, and monitoring prior art are essential to maintain enforceability and defend against challenges.
Sources:
- European Patent Office (EPO) Public Databases.
- Spanish Patent and Trademark Office (OEPM).
- Patent family documents and priority claims.
- Scientific literature on neuroprotective compounds.
- Industry patent landscape reports and industry analyses.
